文拉法辛合并舒必利治疗精神分裂症的临床研究

Clinical Study on Venlafaxine Combined with Sulpiride in Treatment of Schizophrenia

目的探讨文拉法辛合并舒必利治疗精神分裂症的疗效和安全性。方法将68例符合CCMD-3诊断标准的精神分裂症患者随机分为研究组与对照组,研究组给予文拉法辛合并舒必利治疗,对照组用利培酮治疗,疗程8周,用PANSS,CGI,BPRS,TESS评定疗效和安全性。结果治疗8周后文拉法辛合并舒必利组总有效率为88.24%,利培酮组总有效率为67.65%,两组比较有显著性差异(P<0.05)。两组治疗前后PANSS,BPRS评分均有明显下降(P<0.05),两组间比较研究组两量表总分下降更明显,差异有显著性(P<0.05),尤其PANSS中一般精神病理量表分,BPRS中缺乏活力因子分,焦虑抑郁因子分差异显著(P<0.05)。结论文拉法辛合并舒必利治疗精神分裂症阴性与阳性症状疗效可靠,不良反应小,明显提高患者的生活质量。

Objective To probe the efficiency and security of venlafaxine combined with ulpiride on treatment of schizophrenia. Methods 68 schizophrenia patients were divided into two groups randomly, 34 of venlafaxine combining Sulpiride group, 34 of Risperidone group, the period of observation is 8 weeks, assessing efficiency and security of two groups berfore treatment and 1, 2, 4, 6, 8 weeks after treating by PANSS, CGI BPRS and TESS scales. Results All the subjects finished the trail. The total effective rates of two groups were 88.24% and 67. 65%, respectively, there was a significat difference between two groups （P〈0. 05）. The total scores of PANSS and BPRS after and before treatment were significantly descent in each group （P〈0.05）. There was a Significant difference between two groups （P〈0.05）, especially the general psychopathology scale in PANSS, vital impulse defect factor and anxiety depressive factor in BPRS （P〈0. 05）. Conclusion Venlafaxine combining Sulpiride is a effective choice in treatmenting of positive and negative symptoms of/Schizophrenia with light side effects, and it can improve the life quality of schizophrenic consumedly.